Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

Key Points The elucidation of the HIV life cycle from the mid-1980s onwards revealed targets for therapeutic intervention, ultimately leading to the development of several classes of antiretroviral drugs (ARVs), which are now usually combined in specific multidrug regimens. However, such therapy eve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2004-03, Vol.3 (3), p.215-225
Hauptverfasser:	Matthews, Tom, Salgo, Miklos, Greenberg, Michael, Chung, Jain, DeMasi, Ralph, Bolognesi, Dani
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - psychology Animals antiretroviral agents Biomedical and Life Sciences Biomedicine Biotechnology Cancer Research CD4 antigen CD4 lymphocytes CD4-Positive T-Lymphocytes - virology Drug Interactions Drug Resistance, Viral Drug therapy Enfuvirtide Health aspects Highly active antiretroviral therapy HIV (Viruses) HIV Envelope Protein gp41 - pharmacology HIV Envelope Protein gp41 - therapeutic use HIV Fusion Inhibitors - pharmacokinetics HIV Fusion Inhibitors - pharmacology HIV Fusion Inhibitors - therapeutic use HIV-1 - drug effects Human immunodeficiency virus 1 Humans Medicinal Chemistry Molecular Medicine Peptide Fragments - pharmacokinetics Peptide Fragments - pharmacology Peptide Fragments - therapeutic use Pharmacology/Toxicology Physiological aspects Quality of Life review-article
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!